Leukemia MRD detection system based on third-generation sequencing and kit thereof

Through the combination of third-generation sequencing technology and CRISPR-Cas9 principle, the lack of sensitivity and complex operation of leukemia MRD detection in the existing technology is solved, and high-sensitivity MRD detection is achieved, suitable for personalized diagnosis and treatment analysis, reducing false negatives and false positive rate.

CN119020475APending Publication Date: 2024-11-26RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202410950840.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-16
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The existing leukemia microresistance disease (MRD) detection technology has problems such as insufficient sensitivity, complex operation, high cost and difficulty in accurately assessing the MRD levels of patients after clonal evolution and bone marrow transplantation, especially second-generation sequencing cannot be clarified during short sequence assembly. The location of DNA breakage results in a high missed structural variation.

Method used

Using Cas9 targeted enrichment technology based on third-generation sequencing, the DNA sequence of leukemia MRD detection sites is specifically cleaved through the CRISPR-Cas9 principle, combined with ONT PromethIon instrument for sequencing analysis, realizing in-situ detection without amplification, reducing costs and increasing Detection accuracy.

Benefits of technology

High-sensitivity MRD detection is achieved, which can accurately track MRD changes during the treatment process, reduce the false negative and false positive rates, improve the detection ability of tiny missing variants, and is suitable for personalized diagnosis and treatment analysis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020475A_ABST
    Figure CN119020475A_ABST
Patent Text Reader

Abstract

The invention relates to a leukemia MRD detection system based on third-generation sequencing and a kit thereof. According to the detection system and the kit thereof, a Cas9 targeted enrichment third-generation sequencing technology is adopted for detecting MRD specific targets, on one hand, the cost of second-generation sequencing whole genome detection is reduced, on the other hand, targeted sequencing can detect tiny deletion variation sites to reach the sequencing depth of 100 X, and the good market application prospect is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of leukemia detection, and in particular relates to a leukemia MRD detection system based on third-generation sequencing and a kit thereof. Background Art

[0002] Leukemia is a malignant disease of the blood system. Clinically, leukemia is divided into two categories: acute and chronic. The bone marrow of patients with acute leukemia (AL) is mainly composed of primitive cells and early immature cells. The cells differentiate rapidly in a short period of time, and the disease progresses rapidly. Its natural course can be from a few days to a few months. The cells of chronic leukemia (CL) are mostly mature immature cells, and the disease progresses relatively slowly. Some natural courses can last for several years or even decades. Acute leukemia usually seriously threatens the patient's life in a short period of time. Therefore, it is extremely important to actively explore a method to monitor the treatment effect and prognosis of acute leukemia to guide clinical rational treatment. At present, the following indicators are used clinically to judge whether leukemia has achieved the ideal treatment effect, that is, complete remission (CR): the patient has no clinical discomfort such as fever and fatigue; the blood routine is basically normal, and there are no leukemia cells in the white blood cell classification; the immature cells in the bone marrow are ≤5%, there are no Auer bodies, the remaining erythroid and megakaryocyte systems are normal, and no malignant cells are found outside the marrow. After induction remission therapy achieves CR, a small number of malignant cells will still remain in the patient's body. These malignant cells cannot be detected with conventional microscopes. We call these malignant cells that still exist in the patient's body after treatment minimal residual disease (MRD). Minimal residual disease is the root cause of future relapse and refractory treatment of acute leukemia. Reducing minimal residual disease in patients is also a difficult problem that many scholars have been studying and constantly eager to break through, in order to bring patients long-term disease-free survival. In the next few years, more than ten years or even decades, the improvement of leukemia efficacy may mainly depend on the progress in two aspects. One is the clinical application of targeted drugs, and the other is to dynamically evaluate the prognosis of patients based on minimal residual disease for individualized treatment. At present, MRD monitoring has become part of the treatment plan for APL and CML. For acute lymphoblastic leukemia (ALL), there are large-scale multicenter clinical trials underway at home and abroad, studying the application of minimal residual disease monitoring to further improve the efficacy.

[0003] At present, there are mainly the following methods for monitoring leukemia MRD in clinical practice. Cell morphology detection of MRD is to find and classify immature cells under a microscope based on the morphological characteristics (nucleus, cytoplasm and granules) of leukemia tumor cells. Using an optical microscope to manually count the proportion of primitive cells in bone marrow smears is the earliest method used to evaluate the MRD status of leukemia to determine whether the morphology has been relieved, and it is also one of the most common detection methods. The immunological technology used for MRD monitoring is multiparameter flow cytometry (MP-FCM). Multiparameter flow cytometry is a high-throughput, high-sensitivity detection technology that uses a combination of multiple antibodies with different fluorescent labels to detect the expression of surface or intracellular antigens of hematopoietic cells, and then analyzes and judges the series of cell origins, degree of differentiation, and whether the phenotype is abnormal. It has become an indispensable experimental diagnostic method for the diagnosis and typing, treatment monitoring, prognosis evaluation and treatment target screening of malignant blood diseases. At present, the most commonly used flow cytometer is the 8-10 color flow cytometer, which is also one of the most widely used technologies. It can be used for 90% to 99% of patients with hematological tumors, with a sensitivity of 0.0001%. Molecular biology technology monitoring MRD usually refers to the use of PCR technology and NGS technology to detect the quantitative dynamic changes of abnormal genes related to leukemia tumor cells, among which PCR technology mainly refers to RQ-PCR and digital PCR (Droplet Digital PCR); NGS technology mainly detects specific tumor-related targeted gene mutations and clonal identification and MRD monitoring of IG / TCR immune repertoires. The second generation sequencing can detect changes in the load of multiple tumor-related gene mutations (NGS-panel) at one time, and can comprehensively evaluate the factors of tumor subclones, new clones and clonal hematopoiesis. Therefore, compared with the PCR technology of single-site detection of MRD, NGS-panel monitoring of MRD has more advantages, but the sensitivity of ordinary second generation sequencing technology is only about 0.001%. In recent years, people have introduced the method of reducing the error rate of PCR by using molecular tags (UMI), making the sensitivity of NGS-MRD as high as 0.0001%.

[0004] However, these MRD molecular monitoring technologies also have various shortcomings. For example, multi-parameter flow cytometry is limited by the number of detectable surface antigens and the level of technicians, making it difficult to accurately assess the MRD level of patients who have undergone clonal evolution or bone marrow transplantation. The detection of Ig / TCR gene DNA rearrangement and fusion gene (RNA molecule quantification) by RQ-PCR is technically cumbersome, complex to operate, and time-consuming (about two weeks), which limits its promotion. At present, the internationally recognized Euro-MRD Ig / TCR rearrangement BIOMED-2 standard primer system includes 13 PCR primer tubes, which is a large system and cumbersome to operate. In addition, 16% of patients still have misdetection in MRD PCR detection, and TCR / IgH VDJ rearrangement will also change with treatment during treatment, and the rearrangement information cannot be obtained at the time of patient diagnosis, and it is impossible to determine whether the rearrangement has changed later. Although the second-generation sequencing has high detection accuracy, can reduce the chance of missing MRD, and can detect disease recurrence earlier, it can only read 500-600bp in length at a time. It has a good detection rate for small-range structural variations such as SNV and indel, but the omission rate of structural variations greater than 50bp can be as high as 70%. Secondly, more than 56% of the human genome is repeated regions, including centromeres, telomeres and other repeated elements, which makes it impossible for short-read sequencing to clearly determine the specific location of its short sequence during the short sequence assembly process. For example, the P2RY8-CRLF2 fusion caused by the loss of X chromosome PAR1 is difficult to correctly locate the location of the DNA break in the assembly because the breakpoints differ by hundreds of kb. In addition, the latest NCCN guidelines list IKZF1 plus CDKN2A, CDKN2B, PAX5 or PAR1 as landmark mutations with significantly poor prognosis. However, these mutations often represent the loss of DNA fragments on the same chromosome, which is difficult to monitor quantitatively using DNANGS panel, and transcriptome sequencing can only monitor them qualitatively. In addition, the monitoring accuracy is not high, with a median of only 10-2, which makes it difficult to use for MRD monitoring. Although the multiplex ligation-dependent probe amplification (MLPA) analysis launched by MRC in the Netherlands can detect multiple deletions at one time, it is also only judged from a qualitative perspective, and there is a problem of unclear identification of heterozygotes and homozygotes in some patients. In addition, the tiny DNA fragment deletions of malignant gene mutations such as EBF1, BTG1, and ETV6 cannot be used for molecular MRD monitoring based on conventional PCR or second-generation sequencing because the breakpoints are unclear and have personalized differences in different patients.It can be seen from this that both the conventional PCR method and the second-generation sequencing method have underlying defects in the ability to detect a large number of pathogenic malignant gene mutations, and it is difficult to use them as targets to monitor the dynamic changes of MRD during the treatment process. Therefore, the development of new MRD molecular monitoring technology is urgent. Summary of the invention

[0005] The technical problem to be solved by the present invention is to provide a leukemia MRD detection system based on third-generation sequencing and its kit, which reduces the cost and does not require any amplification to achieve in situ detection of MRD genes. In addition, the system of the present application can be used for disease analysis in personalized diagnosis and treatment of subjects. For example, the system and method of the present application can be used to detect the MRD level of the subject during diagnosis of leukemia and subsequent treatment.

[0006] The present invention provides a leukemia MRD detection system based on third-generation sequencing, comprising:

[0007] a) Sample module;

[0008] The sample modules include:

[0009] a1) a sample unit comprising a leukemia cell suspension derived from a subject, wherein the density of the leukemia cells in the suspension is 2×10 7 / ml to 5x10 7 / ml;

[0010] b) at least one detection module for detecting the presence and / or proportion of leukemia cells in the subject;

[0011] Wherein the at least one detection module comprises:

[0012] b1) a cleavage unit comprising an agent capable of specifically cleaving the MRD target gene to obtain an MRD target-specific enriched product;

[0013] The reagents include reagent R1 and reagent R2; the reagent R1 includes crRNA and tracrRNA for each leukemia MRD detection site and Hifi Cas9 protein; the reagent R2 includes QuickCIP enzyme and Taq polymerase.

[0014] Furthermore, the sample module may include:

[0015] a2) a separation unit, comprising a monocyte separation solution for centrifugally separating the leukemia cells of the subject.

[0016] a3) A T cell depletion unit, which is used to deplete T cells from a sample derived from a subject with non-T cell leukemia, thereby obtaining the leukemia cell suspension.

[0017] a4) A DNA extraction unit, which is used to extract the DNA of the leukemia cells, thereby obtaining the DNA product of the leukemia cells.

[0018] Furthermore, the detection module also includes:

[0019] b2) a cutting efficiency identification unit, which comprises reagents and devices for identifying the cutting efficiency of crRNA and tracrRNA at the leukemia MRD detection site, thereby identifying the effectiveness of crRNA and tracrRNA cutting at the leukemia MRD detection site.

[0020] b3) A data analysis unit, which comprises a device for analyzing the data after the cutting of the targeted characteristic enrichment products of the leukemia MRD detection site, so as to obtain the characteristic gene sequence specific to the leukemia cells of the subject.

[0021] Furthermore, the detection module includes two or more detection modules, at least one of which is used to detect the presence and / or proportion of leukemia cells in the subject before the subject receives the treatment, and at least one of which is used to detect the presence and / or proportion of residual leukemia cells in the subject after the subject receives the treatment.

[0022] Furthermore, the detection module targets the subject's DNA product obtained in the above a4), and after using the following one or more MRD gene or fragment crRNA, tracRNA, and Cas9 protein complex, crRNA and tracRNA form gRNA, and then form an RNP complex with cutting function with Cas9 protein, which specifically binds to the corresponding base position, similar to the principle of CRISPR-Cas9, and cuts the DNA sequence of the leukemia MRD detection site, which can be sequenced on the machine to obtain the sequencing result.

[0023] 1) In the detection module, the MRD gene or fragment is one or more of the following: IKZF1, CDKN2A, CDKN2B, PAX5, CRLF2, P2RY8, ERG, ETV6, BTG1, RB1, EBF1.

[0024] 2) In the detection module, the crRNA sequences of the MRD gene or fragment are at least two upstream and downstream of the gene or fragment, and the cleavage sites differ by at least 1 kb.

[0025] 3) The IKZF1 comprises a sequence selected from the group consisting of: SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, and SEQ ID NO.4.

[0026] 4) The CDKN2A comprises a sequence selected from the following group: shown in SEQ ID NO.5 and shown in SEQ ID NO.6.

[0027] 5) The CDKN2B comprises a sequence selected from the following group: shown in SEQ ID NO.7 and shown in SEQ ID NO.8.

[0028] 6) The PAX5 comprises a sequence selected from the following group: shown in SEQ ID NO.9, shown in SEQ ID NO.10, shown in SEQ ID NO.11, shown in SEQ ID NO.12, shown in SEQ ID NO.13, and shown in SEQ ID NO.14.

[0029] 7) The CRLF2 comprises a sequence selected from the following groups: SEQ ID NO.15, SEQ ID NO.16, SEQ ID NO.17, SEQ ID NO.18, SEQ ID NO.19, and SEQ ID NO.20.

[0030] 8) The P2RY8 comprises a sequence selected from the group consisting of SEQ ID NO.21, SEQ ID NO.22, SEQ ID NO.23, SEQ ID NO.24, SEQ ID NO.25, and SEQ ID NO.26.

[0031] 9) The ERG comprises a sequence selected from the following group: SEQ ID NO.27, SEQ ID NO.28, SEQ ID NO.29, SEQ ID NO.30, SEQ ID NO.31, and SEQ ID NO.32.

[0032] 10) The ETV6 comprises a sequence selected from the following group: shown in SEQ ID NO.33, shown in SEQ ID NO.34, shown in SEQ ID NO.35, shown in SEQ ID NO.36, shown in SEQ ID NO.37, and shown in SEQ ID NO.38.

[0033] 11) The BTG1 comprises a sequence selected from the following group: shown in SEQ ID NO.39, shown in SEQ ID NO.40, shown in SEQ ID NO.41, shown in SEQ ID NO.42, shown in SEQ ID NO.43, and shown in SEQ ID NO.44.

[0034] 12) The RB1 comprises a sequence selected from the following group: SEQ ID NO.45, SEQ ID NO.46, SEQ ID NO.47, SEQ ID NO.48, SEQ ID NO.49, and SEQ ID NO.50.

[0035] 13) The EBF1 comprises a sequence selected from the following group: SEQ ID NO.51, SEQ ID NO.52, SEQ ID NO.53, SEQ ID NO.54, SEQ ID NO.55, and SEQ ID NO.56.

[0036] Table 1 crRNA sequences in the kit

[0037]

[0038]

[0039] Table 2 PCR primer sequences in the cutting efficiency identification unit

[0040] name F1 R1 SEQ ID NO PCR1 TCTCAAAACGCGCACAACAG TCTGGACCCATCTCTCCCAG 57、58 PCR2 CCATTGGACTGTGAGCCTGT GCACAGCTGAACTCCTCCAT 59、60 PCR3 TGAGCTCTGCTTCCCAACAG GACATCCCCACTGAAGGAGC 61、62

[0041] Furthermore, the cutting efficiency identification unit has the following characteristics:

[0042] 1) The cutting efficiency identification unit refers to setting PCR primers upstream and downstream of the cutting site to determine whether a DNA fragment can be amplified to identify whether the fragment is cut.

[0043] 2) Taking the IKZF1 gene as an example, the IKZF1 gene site was selected to design PCR primers, comprising sequences selected from the following group: SEQ ID NO.57, SEQ ID NO.58, SEQ ID NO.59, SEQ ID NO.60, SEQ ID NO.61, and SEQ ID NO.62.

[0044] The present invention also provides a leukemia MRD detection kit based on third-generation sequencing, comprising reagents R1 and R2; wherein the reagent R1 comprises crRNA and tracrRNA for each leukemia MRD detection site and Hifi Cas9 protein; and the reagent R2 comprises QuickCIP enzyme and Taq polymerase.

[0045] Furthermore, the leukemia MRD detection sites include one or more of IKZF1, CDKN2A, CDKN2B, PAX5, CRLF2, P2RY8, ERG, ETV6, BTG1, RB1, and EBF1.

[0046] Furthermore, the concentration of the crRNA and tracrRNA is 50-100uM.

[0047] Furthermore, the reagent R1 also includes TE buffer, Nuclease Free Water and 10X CutSmartbuffer.

[0048] Furthermore, the reagent R2 also includes dATP.

[0049] The present invention also provides a method for using a leukemia MRD detection kit based on third-generation sequencing, comprising the following steps:

[0050] (1) Mixing crRNA and tracrRNA to assemble a gRNA double strand;

[0051] (2) diluting 10X CutSmart buffer with Nuclease Free Water to obtain 1.25X CutSmart Buffer; and diluting Hifi Cas9 protein with the 1.25X CutSmart Buffer to obtain diluted Cas9 protein;

[0052] (3) assembling the diluted Cas9 protein and gRNA double strands into a ribonucleoprotein complex, and then adding QuickCIP enzyme, Taq polymerase and dATP for incubation;

[0053] (4) Build the library according to the instructions of the ONT PromethIon instrument, and obtain the leukemia diagnosis results after sequencing analysis.

[0054] The detection system and kit of the present invention can not only track the sequence used as a diagnostic marker, but also detect the newly emerged cancer cell clone sequences, which may indicate the progression or recurrence of the disease. Highly sensitive MRD detection can predict recurrence before clinical symptoms appear and evaluate the treatment effect, which can help doctors take early intervention treatment for patients more timely.

[0055] Beneficial Effects

[0056] (1) The detection system and kit of the present invention use Cas9 targeted enrichment third-generation sequencing technology to monitor the changes in MRD levels during patient treatment. Unlike multi-parameter flow cytometry, it is not limited to a large number of sample cells and the number of surface antigens. It also does not require a lot of experimental experience for operators, thus avoiding the subjectivity of multi-parameter flow cytometry operators. In addition, the depth of MRD detection by ordinary multi-parameter flow cytometry (3-4 colors) is usually 10 -4 , high-throughput multi-parameter flow cytometry (8 colors or more) can reach 10 -6 , but the number of cells required is 2×10 7 ~5×10 7 , remission specimens are generally difficult to obtain; the increase in normal precursor B cells during the bone marrow recovery period may cause a small number of residual leukemia cells to be masked (false negative); with the emergence of immunotherapy such as CAR-T cell therapy, B cell monoclonal antibodies, and BiTE, some commonly used MRD detection targets such as CD19 and CD22 will be affected by drugs. Therefore, multi-parameter flow cytometry is more likely to have false positives and false negatives. Compared with fusion genes and Ig / TCR rearrangements, the immune markers it relies on are less specific than the other two. In addition, factors such as the time the sample is placed, the selection of reagent materials, and operating techniques may also cause errors, bringing difficulties to multi-parameter flow cytometry detection.

[0057] (2) The development time of second-generation sequencing for detecting Ig / TCR gene rearrangement is relatively short, and the technology is relatively immature. The judgment criteria have not been completely unified. The problems that need to be overcome include its reflection of the authenticity of leukemia cells, the selection criteria for significant clones, and standardized detection methods. At the same time, due to the limitation of the short read length of the second-generation sequencing itself, the monitoring effect of small deletion mutations in MRD is poor. The detection system and its kit of the present invention use Cas9 targeted enrichment third-generation sequencing technology to monitor MRD-specific targets. On the one hand, it reduces the cost of second-generation sequencing whole genome detection, and on the other hand, targeted sequencing can detect small deletion mutation sites to a sequencing depth of 20X.

[0058] (3) MLPA technology is a molecular biology technology based on polymerase chain reaction (PCR) and is used to detect copy number variation and sequence variation of genes. It can detect small deletion variations in the MRD stage, but this technology is only a qualitative test, and the results obtained have only three forms of expression - homozygous deletion, heterozygous deletion, and non-deletion. The specific base details of the deletion cannot be obtained from it. In addition, for some samples, MLPA cannot identify clear homozygotes and heterozygotes, which requires accurate sequencing for judgment. The detection system and kit of the present invention use Cas9 targeted enrichment of the third-generation sequencing technology to detect targets included in the MLPA technology, which is a good supplement to MLPA. BRIEF DESCRIPTION OF THE DRAWINGS

[0059] Figure 1 Schematic diagram of the detection system of the present invention.

[0060] Figure 2 Results for the cutting efficiency identification unit: A is a schematic diagram of gRNA cutting the IKZF1 gene; B is a PCR electrophoresis diagram.

[0061] Figure 3 This is the sequencing peak diagram of the kit in Example 2.

[0062] Figure 4 The sequencing depth and coverage of the kit in Example 2 at each MRD detection site. DETAILED DESCRIPTION

[0063] The present invention will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. In addition, it should be understood that after reading the content taught by the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms fall within the scope limited by the appended claims of the application equally.

[0064] In the present application, the term "leukemia" generally refers to a disease caused by the massive proliferation and accumulation of leukemia cells, which usually starts in the bone marrow. The leukemia may include B-cell acute lymphoblastic leukemia and / or T-cell acute lymphoblastic leukemia.

[0065] In this application, the term "subject" generally refers to an individual with a certain disease manifestation, which can refer to the symptoms of the disease or to a harmful physiological state that cannot be changed in a preventive situation. The individual can include males and / or females, and generally includes humans or non-human animals, such as non-human mammals. In certain embodiments, the individual includes, but is not limited to, humans, dogs, cats, horses, sheep, goats, pigs, cattle, rabbits, rats, mice, monkeys, etc. For example, the subject can be a human patient.

[0066] In the present application, the term "sample" generally refers to a sample for the sample unit that can be taken directly or indirectly from a subject and from which a leukemia cell suspension can be obtained. In certain embodiments, the sample taken directly from the subject is not further processed, for example, blood can be obtained from the peripheral circulatory system of the subject (for example, through a blood collection needle). The sample may include, for example, blood, urine, feces, saliva, cerebrospinal fluid, sweat, etc. Non-limiting examples of such samples include blood (or components of blood - e.g., white blood cells, red blood cells, platelets) obtained from any anatomical location of a subject (e.g., tissue, circulatory system, bone marrow), cells obtained from any anatomical location of a subject, skin, heart, lung, kidney, exhaled breath, bone marrow, stool, semen, vaginal fluid, tissue fluid from tumor tissue, breast, pancreas, cerebrospinal fluid, tissue, throat swab, biopsy, placental fluid, amniotic fluid, liver, muscle, smooth muscle, bladder, gall bladder, colon, intestine, brain, cavity fluid, sputum, pus, micropiota, meconium, breast milk, prostate, esophagus, thyroid, serum, saliva, urine, gastric and digestive fluids, tears, ocular fluids, sweat, mucus, cerumen, oils, glandular secretions, spinal fluid, hair, nails, skin cells, plasma, nasal swab or nasopharyngeal wash, spinal fluid, umbilical cord blood, lymph and / or other excreta or body tissues. In certain embodiments, the sample is a bone marrow sample derived from a subject, for example, it contains bone marrow cells and / or blood cells of the subject. For another example, the sample is a bone marrow sample of a leukemia patient, wherein leukemia cells account for more than 90%.

[0067] In this application, the term "suspension" generally refers to a cell suspension formed by one or more cells dispersed in a liquid, wherein the cells can be separated as individuals or in clumps consisting of no more than about 50, no more than about 40, no more than about 30, no more than about 20, no more than about 10 or fewer cells.

[0068] In the present application, the term "leukemia cell" generally refers to an immature white blood cell produced by the pathological differentiation of hematopoietic stem cells. For example, leukemia cells generally do not have the functions of normal cells, but may also have a strong proliferation ability.

[0069] In the present application, the term "cell density" or "density" generally refers to the number of cells contained in a unit volume in a cell suspension. In the present application, a cell suspension can be obtained by using a culture medium, as long as the culture medium can make the cells grow normally. In some embodiments, the culture medium also makes the cells in a suspended state. For example, RPMI cell culture medium can be used to prepare a leukemia cell suspension. For another example, DMEM culture medium, IMDM culture medium, HAMF12 culture medium, MEM culture medium, 199 cell culture medium, MDSS2 cell culture medium, etc. can be used.

[0070] Example 1

[0071] like Figure 1 As shown, this embodiment provides a leukemia MRD detection system based on third-generation sequencing, including:

[0072] a) Sample module;

[0073] The sample modules include:

[0074] a1) a sample unit comprising a leukemia cell suspension derived from a subject, wherein the density of the leukemia cells in the suspension is 2×10 7 / ml to 5x10 7 / ml;

[0075] b) at least one detection module for detecting the presence and / or proportion of leukemia cells in the subject;

[0076] The at least one detection module comprises:

[0077] b1) a cleavage unit comprising an agent capable of specifically cleaving the MRD target gene to obtain an MRD target-specific enriched product;

[0078] The reagents include reagent R1 and reagent R2; the reagent R1 includes crRNA and tracrRNA for each leukemia MRD detection site and Hifi Cas9 protein; the reagent R2 includes QuickCIP enzyme and Taq polymerase.

[0079] Furthermore, the sample module also includes:

[0080] a2) a separation unit, comprising a monocyte separation solution for centrifugally separating the leukemia cells of the subject.

[0081] a3) A T cell depletion unit, which is used to deplete T cells from a sample derived from a subject with non-T cell leukemia, thereby obtaining the leukemia cell suspension.

[0082] a4) A DNA extraction unit, which is used to extract the DNA of the leukemia cells, thereby obtaining the DNA product of the leukemia cells.

[0083] Furthermore, the detection module also includes:

[0084] b2) a cutting efficiency identification unit, which comprises reagents and devices for identifying the cutting efficiency of crRNA and tracrRNA at the leukemia MRD detection site, thereby identifying the effectiveness of crRNA and tracrRNA cutting at the leukemia MRD detection site.

[0085] b3) A data analysis unit, which comprises a device for analyzing the data after the cutting of the targeted characteristic enrichment products of the leukemia MRD detection site, so as to obtain the characteristic gene sequence specific to the leukemia cells of the subject.

[0086] Example 2

[0087] This embodiment provides a leukemia MRD detection kit based on third-generation sequencing, including reagents R1 and R2;

[0088] The components and concentrations of the reagent R1 include:

[0089] 1. pH 7.5 TE buffer;

[0090] 2. 1ul 100uM crRNA and 1ul 100uM tracrRNA for each leukemia MRD detection site;

[0091] 3.50ul Nuclease Free Water(NFW);

[0092] 4.10ul 10X CutSmart buffer;

[0093] 5.1ul Hifi Cas9 protein.

[0094] The components and concentrations of the reagent R2 include:

[0095] 1.3ul QuickCIP enzyme;

[0096] 2.1ul 10mM dATP;

[0097] 3.1ul Taq polymerase.

[0098] This embodiment provides a method for using a leukemia MRD detection kit based on third-generation sequencing, comprising the following steps:

[0099] 1. Resuspend crRNA and tracrRNA in TE buffer at pH 7.5 to a final concentration of 100uM (2nmol crRNA in 20uL; 5nmol tracrRNA in 50uL).

[0100] 2. Mix all crRNAs to be used in equimolar amounts by adding 0.75uL of each crRNA to tube 1.

[0101] 3. Assemble gRNA duplex in tube 2: 8uL NFW, 1uL 100uM tracrRNA, 1uL crRNA mixture.

[0102] 4. Heat the gRNA duplex at 95°C for 5 min and cool on the bench after incubation.

[0103] 5. In tube 3, dilute 10X CutSmart buffer 1:8 with NFW to make 1.25X CutSmart Buffer (14uL NFW + 2uL 10X CutSmart buffer).

[0104] 6. Dilute Hifi Cas9 1:5 with 1.25X CutSmart in tube 4 (1uL HiFi Cas9 + 4uL 1.25X CutSmart).

[0105] 7. Assemble the ribonucleoprotein (RNP) complex in tube 5: 23uL NFW, 2.8uL 10X CutSmartBuffer, 3uL gRNA double-stranded, 1.2uL 1:5 diluted Cas9.

[0106] 8. Stir gently and incubate at room temperature for 20 minutes, then place the RNP on ice.

[0107] 9. Prepare 3uL 10X CutSmart Buffer and 24ul DNA (125ng / ul) in tube 6.

[0108] 10. Add 3uL QuickCIP enzyme to tube 6.

[0109] 11. Incubate tube 6 at the following conditions: 37°C for 10 min, then 80°C for 2 min.

[0110] 12. Add the following components to tube 6: 10uL assembled RNP complex from tube 5, 1uL 10mM dATP, 1uL Taq polymerase, and incubate at 37°C for 15 minutes, then 72°C for 5 minutes, then hold at +12°C.

[0111] 13. Build the library according to the ONT PromethIon instrument instructions, and obtain the leukemia diagnosis results after sequencing analysis.

[0112] In this embodiment, the cleavage efficiency identification is carried out in a leukemia cell line, and the IKZF1 gene is selected as an example. There are one cleavage site gRNA1 and one gRNA2 upstream and downstream of the IKZF1 gene, respectively. PCR primers for the gRNA1 cleavage site, the IKZF1 intergenic site, and the gRNA2 cleavage site are designed ( Figure 2 A). If the site is cut, the corresponding PCR product will be reduced or non-existent, and then the PCR product will be confirmed by DNA agarose electrophoresis. After cutting, it can be clearly seen that the amount of PCR product in the cutting group is less than that in the control group ( Figure 2 B), which indicates that after adding the Cas9-gRNA mixture, the targeted site is partially broken, resulting in a reduction in PCR products, and the CRISPR-Cas9 cutting enrichment method is effective.

[0113] Figure 3 This is the actual test result of the test kit of this embodiment on a certain patient. Figure 3 After the crRNA cleavage site is identified with the above-mentioned consistent cleavage efficiency, the sequencing result visualization diagram obtained by the data analysis unit, in which the horizontal axis is each gene site and the vertical axis is the number of sequencing reads, can be used to know the gene deletion status of the MRD detection site, such as partial exon deletion within the IKZF1 gene and complete deletion of the CDKN2A and CDKN2B genes.

[0114] Figure 4 This is the actual test result of the kit of this example for a certain patient. It analyzes the sequencing depth and sequencing coverage of each MRD detection site, proving that some exons in the IKZF1 gene are deleted, and the CDKN2A and CDKN2B genes are completely deleted.

Claims

1. A leukemia MRD detection system based on third-generation sequencing, comprising: a) Sample module; The sample modules include: a1) a sample unit comprising a leukemia cell suspension derived from a subject, wherein the density of the leukemia cells in the suspension is 2×10 7 / ml to 5x10 7 / ml; b) at least one detection module for detecting the presence and / or proportion of leukemia cells in the subject; The at least one detection module comprises: b1) a cleavage unit comprising an agent capable of specifically cleaving the MRD target gene to obtain an MRD target-specific enriched product; The reagents include reagent R1 and reagent R2; the reagent R1 includes crRNA and tracrRNA for each leukemia MRD detection site and Hifi Cas9 protein; the reagent R2 includes QuickCIP enzyme and Taq polymerase.

2. A leukemia MRD detection system based on third-generation sequencing according to claim 1, characterized in that: The sample module further comprises a2) a separation unit, wherein the separation unit comprises a monocyte separation solution for centrifugally separating the leukemia cells of the subject.

3. A leukemia MRD detection system based on third-generation sequencing according to claim 1, characterized in that: The sample module further comprises a3) a T cell removal unit for removing T cells from a sample derived from a non-T cell leukemia subject, thereby obtaining the leukemia cell suspension.

4. A leukemia MRD detection system based on third-generation sequencing according to claim 1, characterized in that: The sample module also includes a4) a DNA extraction unit, which is used to extract the DNA of leukemia cells, thereby obtaining the DNA products of the leukemia cells.

5. The leukemia MRD detection system based on third-generation sequencing according to claim 1, characterized in that: The detection module also includes b2) a cutting efficiency identification unit, which contains reagents and devices for identifying the cutting efficiency of crRNA and tracrRNA at the leukemia MRD detection site, thereby identifying the effectiveness of crRNA and tracrRNA cutting at the leukemia MRD detection site.

6. A leukemia MRD detection system based on third-generation sequencing according to claim 1, characterized in that: The detection module also includes b3) a data analysis unit, which includes a device for analyzing the data after cutting of the targeted characteristic enrichment product of the leukemia MRD detection site, so as to obtain the characteristic gene sequence specific to the leukemia cells of the subject.

7. A leukemia MRD detection system based on third-generation sequencing according to claim 1, characterized in that: The detection module includes 2 or more detection modules, at least one of which is used to detect the presence and / or proportion of leukemia cells in the subject before the subject receives the treatment, and at least one of which is used to detect the presence and / or proportion of residual leukemia cells in the subject after the subject receives the treatment.

8. A leukemia MRD detection kit based on third-generation sequencing, characterized in that: It includes reagents R1 and R2; wherein the reagent R1 includes crRNA and tracrRNA for each leukemia MRD detection site and Hifi Cas9 protein; and the reagent R2 includes QuickCIP enzyme and Taq polymerase.

9. The detection kit according to claim 8, characterized in that: The leukemia MRD detection sites include one or more of IKZF1, CDKN2A, CDKN2B, PAX5, CRLF2, P2RY8, ERG, ETV6, BTG1, RB1, and EBF1.

10. The detection kit according to claim 8, characterized in that: The reagent R1 also includes TE buffer, Nuclease Free Water and 10X CutSmart buffer.

11. A method for using a leukemia MRD detection kit based on third-generation sequencing, comprising the following steps: (1) Mixing crRNA and tracrRNA to assemble a gRNA double strand; (2) diluting 10X CutSmart buffer with Nuclease Free Water to obtain 1.25X CutSmart Buffer; and diluting Hifi Cas9 protein with the 1.25X CutSmart Buffer to obtain diluted Cas9 protein; (3) assembling the diluted Cas9 protein and gRNA double strands into a ribonucleoprotein complex, adding sample DNA to perform MRD detection site cleavage enrichment, and then adding QuickCIP enzyme, Taq polymerase and dATP for incubation; (4) The library is constructed according to the ONT PromethIon instrument instructions, and then the data analysis unit performs data analysis to obtain the leukemia diagnosis results.

Citation Information

Patent Citations

  • Detection kit and detection method for copy number variation of adult Ph-B-ALL-prognosis-related gene

    CN113373221A

  • System for leukemia diagnosis and treatment

    CN115927621A

  • Acute lymphocytic leukemia related gene capture probe group, kit, library construction method and application

    CN118006773A

  • Polynucleotide enrichment using crispr-CAS systems

    US20160017396A1

  • Methods of enriching for target nucleic acid molecules and uses thereof

    US20230235393A1